Post-earnings recap
Reported
Wed, Oct 30, 2024
EPS actual
$6.39
EPS est.
$6.16
EPS surprise
+3.77%
1-day move
+2.44%
United Therapeutics reported a positive surprise in EPS, which contributed to a 2.44% increase in stock price following the announcement. The lack of revenue data and guidance may leave investors cautious, but the EPS beat indicates strong performance in profitability. Overall, the results suggest a stable outlook for the company, at least in terms of earnings.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $6.39 | N/A | +3.77% |
| Revenue | N/A | N/A | N/A |
Management expressed satisfaction with the EPS results, highlighting ongoing efforts to enhance shareholder value. However, they did not provide detailed guidance for the upcoming quarters.
We are pleased with our EPS performance this quarter.
Our focus remains on delivering value to our stakeholders.
Est. EPS
—
Est. Rev
—
Impl. Move
—